Ricardo Dos Reis

Prof. Ricardo Dos Reis

Chair of Gynecologic Oncology Department at Barretos Cancer Hospital
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YGYasmin Medeiros Guimarães
Yasmin Medeiros Guimarães
LGLuani Godoy
Luani Godoy
ALAdhemar Longatto-Filho
Adhemar Longatto-Filho
RRRicardo Dos Reis
Ricardo Dos Reis
Cervical cancer (CC) remains a public health issue worldwide despite preventive measures. Surgical treatment in the early-stage CC has evolved during the last decades. Our aim was to review the advances in the literature and summarize the ongoing studies on this topic. To this end, we conducted a literature review through PubMed focusing on English-language articles on the surgical management of early-stage CC. The emergent topics considered here are the FIGO 2018 staging system update, conservative management with less radical procedures for selected patients, lymph node staging, fertility preservation, preferred surgical approach, management of tumors up to 2 cm, and prognosis. In terms of updating FIGO, we highlight the inclusion of lymph node status on staging and the possibility of imaging. Regarding the preferred surgical approach, we emphasize the LACC trial impact worldwide in favor of open surgery; however, we discuss the controversial application of this for tumors < 2 cm. In summary, all topics show a tendency to provide patients with tailored treatment that avoids morbidity while maintaining oncologic safety, which is already possible in high-income countries. We believe that efforts should focus on making this a reality for low-income countries as well.

1 September 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
MVMarcelo A. Vieira
Marcelo A. Vieira
GRGabriel J. Rendón
Gabriel J. Rendón
MMMark Munsell
Mark Munsell
LELina Echeverri
Lina Echeverri
MFMichael Frumovitz
Michael Frumovitz
PRPedro T Ramirez
Pedro T Ramirez

1 May 2020 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
GAGuilherme S. Accorsi
Guilherme S. Accorsi
LPLuiza L. Paiva
Luiza L. Paiva
RSRonald Schmidt
Ronald Schmidt
MVMarcelo Vieira
Marcelo Vieira
RRRicardo Dos Reis
Ricardo Dos Reis
CACarlos Andrade
Carlos Andrade

2 March 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
GBGlauco Baiocchi
Glauco Baiocchi
CACarlos Eduardo Mattos Cunha Andrade
Carlos Eduardo Mattos Cunha Andrade
RRReitan Ribeiro
Reitan Ribeiro
RMRenato Moretti-Marques
Renato Moretti-Marques
ATAudrey Tieko Tsunoda
Audrey Tieko Tsunoda
BGBruna Tirapelli Goncalves
Bruna Tirapelli Goncalves
Background Growing evidence suggest that sentinel lymph node (SLN) biopsy in endometrial cancer accurately detects lymph node metastasis. However, prospective randomized trials addressing the oncological outcomes of SLN biopsy in endometrial cancer without lymphadenectomy are lacking. Primary Objectives The present study aims to confirm that SLN biopsy without systematic node dissection does not negatively impact oncological outcomes. Study Hypothesis We hypothesized that there is no survival benefit in adding systematic lymphadenectomy to sentinel node mapping for endometrial cancer staging. Additionally, we aim to evaluate morbidity and impact in quality of life (QoL) after forgoing systematic lymphadenectomy. Trial Design This is a collaborative, multicenter, open-label, non-inferiority, randomized trial. After total hysterectomy, bilateral salpingo-oophorectomy and SLN biopsy, patients will be randomized (1:1) into: (a) no further lymph node dissection or (b) systematic pelvic and para-aortic lymphadenectomy. Major Inclusion and Exclusion Criteria Inclusion criteria are patients with high-grade histologies (endometrioid G3, serous, clear cell, and carcinosarcoma), endometrioid G1 or G2 with imaging concerning for myometrial invasion of ≥50% or cervical invasion, clinically suitable to undergo systematic lymphadenectomy. Primary Endpoint(s) The primary objective is to compare 3-year disease-free survival and the secondary objectives are 5-year overall survival, morbidity, incidence of lower limb lymphedema, and QoL after SLN mapping ± systematic lymphadenectomy in high-intermediate and high-risk endometrial cancer. Sample size 178 participants will be randomized in this study with an estimated date for completing accrual of December 2024 and presenting results in 2027. Trial Registration Number NCT03366051.

17 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
RCRhafaela Causin
Rhafaela Causin
AFAna Julia Aguiar de Freitas
Ana Julia Aguiar de Freitas
CFCassio Murilo Trovo Hidalgo Filho
Cassio Murilo Trovo Hidalgo Filho
RRRicardo Dos Reis
Ricardo Dos Reis
RRRui M. Reis
Rui M. Reis
MMMarcia Marques
Marcia Marques
To obtain a better understanding on the role of microRNAs in the progression of cervical cancer, a systematic review was performed to analyze cervical cancer microRNA studies. We provide an overview of the studies investigating microRNA expression in relation to cervical cancer (CC) progression, highlighting their common outcomes and target gene interactions according to the regulatory pathways. To achieve this, we systematically searched through PubMed MEDLINE, EMBASE, and Google Scholar for all articles between April 2010 and April 2020, in accordance with the PICO acronym (participants, interventions, comparisons, outcomes). From 27 published reports, totaling 1721 cases and 1361 noncancerous control tissue samples, 26 differentially expressed microRNAs (DEmiRNAs) were identified in different International Federation of Gynecology and Obstetrics (FIGO) stages of cervical cancer development. It was identified that some of the dysregulated microRNAs were associated with specific stages of cervical cancer development. The results indicated that DEmiRNAs in different stages of cervical cancer were functionally involved in several key hallmarks of cancer, such as evading growth suppressors, enabling replicative immortality, activation of invasion and metastasis, resisting cell death, and sustained proliferative signaling. These dysregulated microRNAs could play an important role in cervical cancer’s development. Some of the stage-specific microRNAs can also be used as biomarkers for cancer classification and monitoring the progression of cervical cancer.

16 October 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
DCDavid Cibula
David Cibula
LDLukáš Dostálek
Lukáš Dostálek
JJJiri Jarkovsky
Jiri Jarkovsky
CMConstantijne H. Mom
Constantijne H. Mom
ALAldo Lopez
Aldo Lopez
LLLuc R.C.W. van Lonkhuijzen
Luc R.C.W. van Lonkhuijzen